Kaló Z - Search Results

1

Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes.

Nagy B, Zsólyom A, Nagyjánosi L, Merész G, Steiner T, Papp E, Dessewffy Z, Jermendy G, Winkler G, Kaló Z, Vokó Z. Nagy B, et al. Among authors: kalo z. Diabetes Metab Res Rev. 2016 Oct;32(7):710-729. doi: 10.1002/dmrr.2791. Epub 2016 May 1. Diabetes Metab Res Rev. 2016. PMID: 26888326

2

Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments.

Redekop WK, Stolk EA, Kok E, Lovas K, Kalo Z, Busschbach JJ. Redekop WK, et al. Among authors: kalo z. Diabetes Metab. 2004 Dec;30(6):549-56. doi: 10.1016/s1262-3636(07)70154-4. Diabetes Metab. 2004. PMID: 15671925

3

Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development.

Bodrogi J, Kaló Z. Bodrogi J, et al. Among authors: kalo z. Br J Pharmacol. 2010 Apr;159(7):1367-73. doi: 10.1111/j.1476-5381.2009.00550.x. Epub 2010 Feb 2. Br J Pharmacol. 2010. PMID: 20132213 Free PMC article. Review.

4

Health technology assessment: a European collaboration.

Kaló Z, Vokó Z. Kaló Z, et al. Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):41-3. doi: 10.1586/erp.10.90. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 21351855

5

[Assessment of the pharmaceutical expenditure in Hungary].

Inotai A, Merész G, Kaló Z. Inotai A, et al. Among authors: kalo z. Acta Pharm Hung. 2010;80(4):162-72. Acta Pharm Hung. 2010. PMID: 21404477 Hungarian.

6

Modeling cost-effectiveness of cervical cancer screening in Hungary.

Vokó Z, Nagyjánosi L, Margitai B, Kövi R, Tóth Z, László D, Kaló Z. Vokó Z, et al. Among authors: kalo z. Value Health. 2012 Jan;15(1):39-45. doi: 10.1016/j.jval.2011.10.003. Value Health. 2012. PMID: 22264970 Free article.

7

Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries.

Kaló Z, Landa K, Doležal T, Vokó Z. Kaló Z, et al. Eur J Cancer Care (Engl). 2012 Jul;21(4):442-9. doi: 10.1111/j.1365-2354.2012.01351.x. Epub 2012 Apr 18. Eur J Cancer Care (Engl). 2012. PMID: 22510226

8

Pitfalls associated with the therapeutic reference pricing practice of asthma medication.

Kalo Z, Abonyi-Toth Z, Bartfai Z, Voko Z. Kalo Z, et al. BMC Pulm Med. 2012 Jul 20;12:35. doi: 10.1186/1471-2466-12-35. BMC Pulm Med. 2012. PMID: 22818402 Free PMC article.

9

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.

Vokó Z, Nagyjánosi L, Kaló Z. Vokó Z, et al. Among authors: kalo z. BMC Public Health. 2012 Oct 30;12:924. doi: 10.1186/1471-2458-12-924. BMC Public Health. 2012. PMID: 23110361 Free PMC article.

10

The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids.

Nagy B, Timár G, Józwiak-Hagymásy J, Kovács G, Merész G, Vámossy I, Ágh T, László Á, Vokó Z, Kaló Z. Nagy B, et al. Among authors: kalo z. Eur J Obstet Gynecol Reprod Biol. 2014 Apr;175:75-81. doi: 10.1016/j.ejogrb.2014.01.022. Epub 2014 Jan 31. Eur J Obstet Gynecol Reprod Biol. 2014. PMID: 24568866

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

188 results

Search Page

Filters